MedTrace Logo

Multi-cancer Joint Screening and Early Diagnosis and Treatment Project Based on the Combination of Chinese Traditional and Western Medicine in Lanxi City

NCT06200051 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-07-28

No results posted yet for this study

Summary

This study conducted a joint screening and early diagnosis and recommended treatment for LCA, LC, UGIC, and CRC among residents aged 45 to 74 in six townships of Lanxi City, Zhejiang Province. Residents who voluntarily participated and signed informed consent forms completed cancer risk assessment questionnaires and traditional Chinese medicine spleen deficiency (TCM-SD) investigations. The cancer risk assessment model established by the National Cancer Center was utilized to assess individual cancer risk scores. Simultaneously, blood samples (three tubes), one stool sample, and one urine sample were collected from each participant. Clinical screenings, including low-dose spiral CT, gastroscopy, colonoscopy, alpha-fetoprotein (AFP), and abdominal ultrasound, were performed for individuals identified as high-risk through the assessment.

Conditions

  • Cancer Screening

Interventions

DIAGNOSTIC_TEST

Prediction of high risk of cancer

This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.

Sponsors & Collaborators

  • Zhejiang Chinese Medical University

    collaborator OTHER_GOV

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Lanxi Hospital of Traditional Chinese Medicine

    lead OTHER

Eligibility

Min Age
45 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-12
Primary Completion
2024-03-05
Completion
2024-05-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06200051 on ClinicalTrials.gov